Thomas Danne is Director of the Department of General Paediatrics, Endocrinology/Diabetology and Clinical Research at the Auf der Bult Hospital for Children and Adolescents, Hannover Medical School, Germany. He is a former Research Fellow of the Joslin Diabetes Centre, Harvard Medical School, USA.
His research interests include basic and clinical research in paediatric diabetology, particularly new insulins, insulin pumps, glucose sensors and the artificial pancreas. He has published more than 300 research papers and is a principal investigator of international multi-centre studies. These include the DREAM consortium for treating children with diabetes with automated-insulin delivery. Currently, he is Chairman of the SWEET project which aims to reduce inequalities in access to and quality of pediatric diabetes care worldwide with more than 150 contributing diabetes centers worldwide. He is also a work-package leader of the INNODIA project, a global partnership providing a pan-European reference point for conducting studies to prevent or cure type 1 diabetes.
Professor Danne has various society affiliations, including as Past President of the International Society for Paediatric and Adolescent Diabetes (ISPAD), the International Diabetes Federation, and Past President of the German Diabetes Association.
Duality of Interest: Professor Danne has received research support/grants from Abbott, Astra Zeneca, Boehringer, Dexcom, Eli Lilly, Medtronic, NovoNordisk and Sanofi, and speaker’s fees/honoraria from Abbott, Astra Zeneca, Dexcom, Eli Lilly, Medtronic, NovoNordisk, Roche and Sanofi. He has also received payments for membership of boards/advisory panels from Abbott, Astra Zeneca, Dexcom, Eli Lilly, Medtronic, NovoNordisk, Roche and Sanofi and has Stocks/Shares/ Directorships with DreaMed.
Date: Summer 2022